M. Stonier
Bristol-Myers Squibb (Germany)(DE)Bristol-Myers Squibb (United States)(US)
Publications by Year
Research Areas
HIV/AIDS drug development and treatment, Pharmacogenetics and Drug Metabolism, Hepatitis C virus research, Drug Transport and Resistance Mechanisms, HIV Research and Treatment
Most-Cited Works
- → Pharmacodynamics, Safety, and Pharmacokinetics of BMS-663068, an Oral HIV-1 Attachment Inhibitor in HIV-1-Infected Subjects(2012)105 cited
- → Organic Anion Transporting Polypeptide‐Mediated Transport of, and Inhibition by, Asunaprevir, an Inhibitor of Hepatitis C Virus NS3 Protease(2014)45 cited
- → Pharmacokinetics and safety of twice-daily atazanavir 300 mg and raltegravir 400 mg in healthy individuals(2010)31 cited
- → Determination of rifabutin dosing regimen when administered in combination with ritonavir-boosted atazanavir(2011)19 cited
- → Use of a cocktail probe to assess potential drug interactions with cytochrome P450 after administration of belatacept, a costimulatory immunomodulator(2016)16 cited
- → P0790 : The effect of renal impairment on multiple-dose pharmacokinetics of the fixed-dose combination of daclatasvir/asunaprevir/beclabuvir(2015)5 cited
- → 822Effect of Steady State Daclatasvir Plus Asunaprevir on the Single Dose Pharmacokinetics of the P-glycoprotein Substrate Digoxin in Healthy Adult Subjects(2014)4 cited
- → The pharmacokinetics of peginterferon lambda‐1a following single dose administration to subjects with impaired renal function(2015)3 cited
- → P0839 : Evaluation of drug–drug interactions between the fixed-dose combination of daclatasvir/asunaprevir/beclabuvir and methadone or buprenorphine/naloxone(2015)1 cited
- → P1140 PEGINTERFERON LAMBDA-1a PHARMACOKINETICS IN SUBJECTS WITH IMPAIRED RENAL FUNCTION(2014)